# Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

> **NCT06397963** · NA · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 18 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** GT307 injection

## Key facts

- **NCT ID:** NCT06397963
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-18
- **Primary completion:** 2027-04-18
- **Final completion:** 2027-04-18
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397963, "Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06397963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*